Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions

Kidney International

Volumn 83, Issue 4, 2013, Pages 715-723

  Wu, Li Hua ^a,b   Yu, Feng ^a   Tan, Ying ^a   Qu, Zhen ^a   Chen, Meng Hua ^b   Wang, Su Xia ^a   Liu, Gang ^a   Zhao, Ming Hui ^a,c  

^a PEKING UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

^c Tsinghua University   (China)

Author keywords

lupus nephritis; renal vascular lesions; SLE

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ATHEROSCLEROSIS; CHINA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG TREATMENT FAILURE; FEMALE; GLOMERULONEPHRITIS; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX DEPOSITION; INTERSTITIAL NEPHRITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NECROTIZING ARTERITIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RENOVASCULAR DISEASE; RISK FACTOR; SCORING SYSTEM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

EID: 84875743388     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.409     Document Type: Article

References (41)

1. D'Agati VD. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren's syndrome, and rheumatoid arthritis. In: Jennette JC, OJL SchwartzMMea (eds). Heptinstall's Pathology of the Kidney, 6th edn. Lippincott-Raven: Philadephia, 2007; pp 517-612.
2. Appel GB, D'Agati RJ. Secondary glomerular disease. In: Brenner BM (ed). Brenner & Rector's The Kidney, 8th edn. W.B.Saunders: Philadephia, 2008; pp 1067-1146.
3. Banfi G, Bertani T, Boeri V et al. Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 1991; 18: 240-248.
4. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4: 1499-1515.
5. McCluskey R. Lupus Nephritis. Appleton-Centery-Crofts: East Norwalk, CT, 1975.
6. Churg J, Sobin L. Renal Disease: Classification and Atlas of Glomerular Disease. Igaku-Shoin: Tokyo, 1982.
7. Churg J, Bernstein J, Classock RJ. Renal Disease: Classification and Atlas of Glomerular Disease. Igaku-Shoin: Tokyo, 1995.
8. Muenz AHA 3rd, Muenz LR, Joyce KM et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
9. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530.
10. Cervera R, Abarca-Costalago M, Abramovicz D et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the 'Euro-Lupus Project'. Autoimmun Rev 2006; 5: 180-186.
11. Cervera R, Font J, Shoenfeld Y. European Working Party on Systemic Lupus Erythematosus: a 15-year report. Autoimmun Rev 2006; 5: 549-553.
12. Grishman E, Venkataseshan VS. Vascular lesions in lupus nephritis. Mod Pathol 1988; 1: 235-241.
13. Appel GB, Silva FG, Pirani CL et al. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57: 371-410.
14. Appel GB, Cohen DJ, Pirani CL et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-885.
15. Trouw LA, Groeneveld TW, Seelen MA et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114: 679-688.
16. Porta C, Caporali R, Montecucco C. Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects. Haematologica 1999; 84: 260-269.
17. Vasoo S, Thumboo J, Fong KY. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus 2002; 11: 443-450.
18. Letchumanan P, Ng HJ, Lee LH et al. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford) 2009, 48: 399-403.
19. Silvarino R, Sant F, Espinosa G et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus 2011; 20: 721-729.
20. Zheng H, Chen Y, Ao W et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res Ther 2009; 11: R93.
21. Cohen D, Koopmans M, Kremer HIC et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 2008; 58: 2460-2469.
22. Shen Y, Chen XW, Sun CY et al. Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus 2010; 19: 1195-1203.
23. Baldwin DS, Gluck MC, Lowenstein J et al. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med 1977; 62: 12-30.
24. Tsumagari T, Fukumoto S, Kinjo M et al. Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol 1985; 16: 43-49.
25. Abdellatif AA, Waris S, Lakhani A et al. True vasculitis in lupus nephritis. Clin Nephrol 2010; 74: 106-112.
26. Urowitz MB, Bookman AA, Koehler BE et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
27. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
28. Thacker SG, Berthier CC, Mattinzoli D et al. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated byrepression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010; 185: 4457-4469.
29. Clancy R, Ginzler EM. Endothelial function and its implications for cardiovascular and renal disease in systemic lupus erythematosus. Rheum Dis Clin North Am 2010; 36: 145-160.
30. Lewis MJ, Malik TH, Fossati-Jimack L et al. Combining lupus and hyperlipidaemia in mice reveals distinct roles for complement in glomerulonephritis and atherosclerosis. Arthritis Rheum 2012. e-pub ahead of print.
31. Austin HA 3rd, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.
32. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904-914.
33. Hiramatsu N, Kuroiwa T, Ikeuchi H et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford) 2008; 47: 702-707.
34. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
35. Descombes E, Droz D, Drouet L et al. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997; 76: 355-368.
36. Roberts IS, Cook HT, Troyanov S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556.
37. Wang J, Hu W, Xie H et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16: 707-712.
38. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
39. Chan TM, Tse KC, Tang CS et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-272.
40. Wang HY, Cui TG, Hou FF et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008; 17: 638-644.
41. Yu F, Tan Y, Liu G et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009; 76: 307-317.